Clinical trials: Autoimmune Anemia
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study. The primary objective is to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of YTS109 START T-cell therapy…
- Conditions
- Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy, Failure ≥3 Lines of Therapies
- Trial name
- NCT06770504
- Testing
- YTS109
- Volunteers
- 7 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematologic Malignancies, Inherited Disorders of Metabolism
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
- Conditions
- Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders
- Trial name
- NCT01351545
- Testing
- A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
- Where
- 142 sites in United States
- Volunteers
- 99,999 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Refractory/Relapsed Autoimmune Hemolytic Anemia
The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
The sample size of this study is calculated based on Simon's two-stage design. The first stage of the study enrolled a cohort of 12 patients.
- Trial name
- NCT06021977
- Testing
- Zanubrutinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Diabetes Mellitus, Hypertension
Evidence-based Laboratory Test Order Sets in Primary Care
Cluster randomised controlled trial to evaluate what the effect is of evidence-based order sets aimed at five indications on the appropriateness of laboratory test ordering in primary care.
- Conditions
- Diabetes Mellitus, Hypertension, Cardiovascular Diseases, Fatigue
- Trial name
- NCT02950142
- Testing
- CPOE with order sets for lab testing, CPOE without order sets for lab testing
- Where
- Belgium
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Moderate Aplastic Anemia, Unilineage Bone Marrow Failure Disorders
Eltrombopag for Moderate Aplastic Anemia
Background: Moderate aplastic anemia is a blood disease which may require frequent blood and platelet transfusions. Sometimes patients with this disease can be treated with immunosuppressive drugs.
- Trial name
- NCT01328587
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant…
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias
- Trial name
- HSCT+RIC (NCT01962415)
- Testing
- Hydroxyurea, Alemtuzumab, Fludarabine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Paul Szabolcs
Anemia
A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies
The purpose of this study is to assess the presence of anti erythropoietin antibodies (anti EPO Ab) in participants responding to any erythropoietin receptor agonist (ERA) therapy to treat or prevent anemia without loss of…
- Trial name
- NCT00210977
- Testing
- No intervention
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Primary Immune Thrombocytopenia, Aplastic Anemia
An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
This is a multi-center, observational study in patients with Immune Thrombocytopenia (ITP) or aplastic anemia(AA) designed to describe the real-world safety and effectiveness of hetrombopag and assess the patterns of drug…
- Trial name
- NCT05333861
- Testing
- hetrombopag
- Where
- China
- Volunteers
- 1,150 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hereditary Spherocytosis, Idiopathic Thrombocytopenic Purpura
Single Incision Versus Standard Laparoscopic Splenectomy
This is a prospective trial of single incision versus standard 4-port laparoscopic splenectomy. The hypothesis is that there may be a difference in wound infection rates, operative time, doses of analgesics post-operatively, and…
- Trial name
- NCT01276561
- Testing
- Single Incision Splenectomy, Laparoscopic Splenectomy
- Where
- United States
- Sponsor
- Children's Mercy Hospital Kansas City
Aplastic Anemia
Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia
This study will examine the safety and effectiveness of a new drug combination for treating patients with severe aplastic anemia.
- Trial name
- NCT00005935
- Testing
- Mycophenolate mofetil, Cyclosporine
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Pain
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having severe to moderate chronic pain.
- Trial name
- NCT01206907
- Testing
- oxymorphone IR
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
POEMS Syndrome, Amyloidosis
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
- Conditions
- POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, Vasculitis
- Trial name
- NCT05263817
- Testing
- CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Zhejiang University
Purpura, Schoenlein-Henoch, Graft Versus Host Disease
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II.
- Conditions
- Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis
- Trial name
- NCT00006055
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fairview University Medical Center
AIHA - Warm Autoimmune Hemolytic Anemia, UCART
UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in AIHA who have failed ≥ 3 lines of therapy
- Trial name
- NCT07530380
- Testing
- QT-219C Cell Injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Second Hospital of Anhui Medical University
Autoimmune Hemolytic Anemia
The Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic Anemia Before and After Tratment
we study the circulating T-follicular regulatory and T-follicular regulatory cells in autoimmune hemolytic anemia.
- Trial name
- fhfr (NCT04814394)
- Testing
- flowcytometry
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Ultomiris-exposed Pregnant/ Postpartum, Pregnancy
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of…
- Conditions
- Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)
- Trial name
- NCT06312644
- Testing
- Ultomiris
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 75 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Alopecia Areata, Alopecia Totalis
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
The study series consists of three studies with the aim to assess the incidence, prevalence, risk factors, comorbidities and management of patients with alopecia areata in Czech Republic based on the patients and registry of a…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Alopecia Areata (& Ophiasis)
- Trial name
- NCT05098600
- Testing
- Exposure of interest
- Where
- Czechia
- Volunteers
- 123 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Autoimmune Hemolytic Anemia
Data Registry of Auto Immune Hemolytic Anemia
In autoimmune hemolytic anemia (AIHA) auto-antibodies directed against red blood cells (RBCs) lead to increased RBC clearance (hemolysis). This can result in a potentially life-threatening anemia.
- Trial name
- DRAIHA (NCT04024202)
- Where
- 2 sites in Netherlands
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Sanquin Research & Blood Bank Divisions